PETROS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4241 USD | -1.35% |
|
-3.28% | -69.92% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 4.825 | 3.104 | 2.969 | - | - |
| Enterprise Value (EV) 1 | 4.825 | 3.104 | 2.969 | 2.969 | 2.969 |
| P/E ratio | -0.24 x | -0.22 x | -0.1 x | -0.13 x | -0.17 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 0.53 x | 0.55 x | 0.54 x | 0.27 x |
| EV / Revenue | - | 0.53 x | 0.55 x | 0.54 x | 0.27 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | -14,89,958 x | - | - | - |
| FCF Yield | - | -0% | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 2,071 | 2,201 | 7,000 | - | - |
| Reference price 2 | 2.330 | 1.410 | 0.4241 | 0.4241 | 0.4241 |
| Announcement Date | 31/03/23 | 01/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 5.822 | 5.409 | 5.475 | 11.03 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -13.62 | -14.75 | -14.99 | -11.34 |
| Operating Margin | - | -233.88% | -272.64% | -273.84% | -102.84% |
| Earnings before Tax (EBT) 1 | - | -8.163 | -13.44 | -15.6 | -11.95 |
| Net income 1 | -20.04 | -13.81 | -19.3 | -15.6 | -11.95 |
| Net margin | - | -237.26% | -356.91% | -285.02% | -108.39% |
| EPS 2 | -9.680 | -6.350 | -4.050 | -3.260 | -2.490 |
| Free Cash Flow | - | -2.083 | - | - | - |
| FCF margin | - | -35.77% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 31/03/23 | 01/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | -0.3642 | 1.389 | 1.397 | 1.34 | 1.283 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -5.039 | -3.928 | -3.518 | -3.606 | -3.695 |
| Operating Margin | 1,383.29% | -282.85% | -251.83% | -269.1% | -288% |
| Earnings before Tax (EBT) 1 | 0.3182 | -2.163 | -3.671 | -3.759 | -3.848 |
| Net income 1 | -4.994 | -8.027 | -3.671 | -3.759 | -3.848 |
| Net margin | 1,370.99% | -577.97% | -262.78% | -280.52% | -299.92% |
| EPS 2 | -2.170 | -1.690 | -0.7700 | -0.7900 | -0.8100 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 01/04/24 | 15/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -2.08 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 31/03/23 | 01/04/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.4241
USD
Average target price
4
USD
Spread / Average Target
+843.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.92% | 2.97M | |
| +16.59% | 44.44B | |
| +41.02% | 39.84B | |
| -10.62% | 37.68B | |
| +29.92% | 31.46B | |
| -9.23% | 27.02B | |
| +12.34% | 26.29B | |
| +41.53% | 13.8B | |
| +31.49% | 12.46B | |
| -7.40% | 11.26B |
- Stock Market
- Equities
- PTPI Stock
- Financials Petros Pharmaceuticals, Inc.
